Rigel Pharmaceuticals (RIGL) investor relations material

Strategic imperatives and commercial growth

• Four strategic imperatives: commercial business growth, in-licensing/business development, advancing the pipeline, and maintaining financial discipline.

• Transformation from one commercial product in 2020 to three by 2025, with plans for four by the 2030s, supported by a robust pipeline and M&A opportunities.

• Three commercial products grew 14% year-over-year in Q2, reaching $8.1 million in net revenues.

• Global collaborations generated $11.7 million in Q2, with partners in Europe, Japan, Canada, Israel, and Latin America.

• Eight consecutive profitable quarters, strong cash position, and solid financial footing.

Commercial performance and global expansion

• Q2 2026 net product sales reached $67.0M, a 14% increase over Q2 2025, driven by TAVALISSE, GAVRETO, and REZLIDHIA.

• TAVALISSE is now available in key European countries, Japan, South Korea, Canada, Israel, and recently launched in Mexico and approved in Brazil.

• Collaboration revenues in Q2 2026 totaled $11.7M, with significant contributions from Kissei and Grifols.

VEPPANU launch and market opportunity

• VEPPANU is the first and only FDA-approved PROTAC, targeting ER-positive, HER2-negative, ESR1-mutated advanced/metastatic breast cancer after endocrine therapy.

• Market opportunity exceeds $1 billion, with 20,000 eligible second/third-line patients in the U.S.

• Demonstrated superior efficacy and tolerability versus fulvestrant, with rapid adoption plans and omnichannel promotional campaigns underway.

• NCCN guidelines now include VEPPANU; launch supported by trained sales force and patient services.

• VEPPANU launched in the U.S. within 60 days of transaction close, leveraging existing infrastructure for rapid commercialization.